mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.011 |
0.8 |
mRNA |
SCH-529074 |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.8 |
mRNA |
MK-2206 |
GDSC1000 |
pan-cancer |
AAC |
-0.011 |
0.8 |
mRNA |
Pyrimethamine |
GDSC1000 |
pan-cancer |
AAC |
0.016 |
0.8 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.8 |
mRNA |
SID 26681509 |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.8 |
mRNA |
BRD-K42260513 |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.8 |
mRNA |
C6-ceramide |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.8 |
mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.8 |
mRNA |
PIK-93 |
CTRPv2 |
pan-cancer |
AAC |
0.011 |
0.8 |